News

Daré Bioscience Launches “CEO Corner” Video Series to Highlight the Company’s Pipeline of Women’s Health Innovations, Corporate Strategy and Opportunities

New video series featuring Founder, President and CEO Sabrina Martucci Johnson will provide investors with insights into Daré Bioscience’s growing commercial portfolio, clinical pipeline and strategic priorities Access the CEO Corner here SAN DIEGO, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced the launch of its

Yahoo·09:15DARE▲+5.3%

12 Health Care Stocks Moving In Monday's After-Market Session

Gainers Biomea Fusion (NASDAQ:BMEA) stock increased by 11.0% to $1.51 during Monday's after-market session. The market value of their outstanding shares is at $102.9 million. iTonic Holdings (NASDAQ:ITOC) shares

Benzinga·13:05

Daré Bioscience to Present Phase 1 Sildenafil Cream Data at Sexual Medicine Society of North America (SMSNA) Annual Fall Scientific Meeting

Medical Director Annie Thurman, MD, FACOG to present adverse event and relative bioavailability data comparing topical Sildenafil Cream with oral sildenafil in healthy male adultsSAN DIEGO, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that clinical data from a Phase 1 study that evaluated the Company’s proprieta

Yahoo·09:15DARE▲+5.3%

Daré Bioscience To Present Clinical Data From A Phase 1 Study Evaluating Sildenafil Cream, 3.6% Investigational Product At The Sexual Medicine Society Of North America Meeting, October 8-11

linical data from a Phase 1 study that evaluated the Company’s proprietary Sildenafil Cream, 3.6% investigational product (Sildenafil Cream) will be presented at the Annual Fall Scientific Meeting of the Sexual Medicine

Benzinga·05:21

Dare Bioscience stock rises after receiving HPV treatment patent

Investing.com -- Dare Bioscience Inc (NASDAQ:DARE) shares rose 2.8% on Monday following the announcement that the company received a new U.S. patent for its HPV treatment program.

Yahoo·10:32DARE▲+5.3%

Dare Bioscience Announces New U.S. Patent Strengthening DARE-HPV Program as a Potential First FDA-Approved Pharmacologic Treatment for HPV Infection

New U.S. patent expands intellectual property foundation for DARE-HPV, a potential first-in-category treatment targeting persistent high-risk HPV infection DARE-HPV Phase 2 study underway with topline results expected in 2027; program supported by approximately $10 million in non-dilutive ARPA-H funding and a $2.0 million NIAID award DARE-HPV is designed to address a major treatment gap for the millions of U.S. women who experience high-risk HPV infection each year, for which there is currently

Yahoo·08:20DARE

Daré Bioscience Receives U.S. Patent For Its Pharmaceutical Compositions Formulated For Topical Application Comprising Lopinavir, Ritonavir To Treat Cervical Pathologies

Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced the issuance of

Benzinga·04:21DARE▲+5.3%

Daré Bioscience Announces Peer-Reviewed Publication of Phase 1 Sildenafil Cream Study in Men Demonstrating Substantially Lower Systemic Exposure Versus Oral Sildenafil

Published Phase 1 data in Sexual Medicine strengthen the scientific foundation for Daré Bioscience’s proprietary topical Sildenafil Cream, 3.6% At the 71 mg topical dose, mean maximum plasma concentration of sildenafil was approximately 187-fold lower than following a 50 mg oral dose Publication expands peer-reviewed clinical evidence supporting Daré Bioscience’s proprietary topical Sildenafil Cream formulation SAN DIEGO, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a

Yahoo·08:50DARE▲+5.3%

Daré Bioscience Announces Publication Of Results From A Phase 1 Clinical Study Evaluating Safety And Systemic Pharmacokinetics Of Topical Sildenafil Cream, 3.6%, In Healthy Adult Men In The Journal Sexual Medicine; At 71 Mg Topical Dose, Mean Maximum Plasma Concentration Of Sildenafil Was ~187-Fold Lower Than Following A 50 Mg Oral Dose

The article, titled, "An open-label, single-dose, randomized, parallel-group study of the safety and relative bioavailability of topical sildenafil cream vs oral sildenafil in healthy male adults," discusses

Benzinga

Daré Bioscience Presentation for H.C. Wainwright 28th Annual Global Investment Conference Now Available On-Demand

View the video webcast here SAN DIEGO, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that its pre-recorded presentation for the H.C. Wainwright 28th Annual Global Investment Conference is now available for on-demand viewing here. The presentation, featuring Sabrina Martucci Johnson, President and Chief Executive

Yahoo·06:55DARE▲+5.3%

12 Health Care Stocks Moving In Wednesday's After-Market Session

Gainers EXoZymes (NASDAQ:EXOZ) stock increased by 7.5% to $7.18 during Wednesday's after-market session. The market value of their outstanding shares is at $58.5 million. AEON Biopharma (AMEX:AEON) shares rose

Benzinga·13:06

12 Health Care Stocks Moving In Friday's Intraday Session

Gainers MDxHealth (NASDAQ:MDXH) stock moved upwards by 120.8% to $1.02 during Friday's regular session. The company's market cap stands at $23.7 million. The company's, Q2 earnings came out yesterday.

Benzinga·09:06

Daré Bioscience Announces $6M Offering Of 4,379,581 Shares (Or Pre-Funded Warrants To Purchase Shares Of Common Stock In Lieu Thereof) At $1.37/Share

Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, today announced that it has entered

Benzinga·08:47DARE▲+5.3%

Daré Bioscience, Inc. (DARE) Q2 2026 Earnings Call Transcript

Daré Bioscience, Inc. (DARE) Q2 2026 Earnings Call August 13, 2026 4:30 PM EDTCompany ParticipantsMarDee Haring-Layton - Chief Accounting OfficerSabrina...

SeekingAlpha·17:47DARE▲+5.3%

Stay updated with the stocks that are on the move in today's after-hours session.

The US market regular session of Thursday is over, let's have a look at the top gainers and losers in the after hours session today.

ChartMill·17:00

Dare Bioscience Reports Q2 2026 Results: Full Earnings Call Transcript

Dare Bioscience (NASDAQ:DARE) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For real-time

Benzinga·13:25DARE▲+5.3%

12 Health Care Stocks Moving In Thursday's After-Market Session

Gainers Akanda (NASDAQ:AKAN) stock rose 109.4% to $10.49 during Thursday's after-market session. The company's market cap stands at $2.9 million. Capricor Therapeutics (NASDAQ:CAPR) stock moved upwards by

Benzinga·13:06

Dare Bioscience Q2 EPS $(0.20) Beats $(0.24) Estimate, Sales $187.546K Beat $2.000K Estimate

Dare Bioscience (NASDAQ:DARE) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.24) by 16.67 percent. This is a 55.56 percent increase over losses of $(0.45) per share from

Benzinga·12:02DARE▲+5.3%

Daré Bioscience, Inc. (DARE) Discusses Portfolio Advancements and Therapeutic Solutions for Women's Health Transcript

SeekingAlpha·12:57DARE▲+5.3%

Daré Bioscience, Inc. (DARE) Discusses Women's Health Portfolio and Commercialization Highlights on Virtual Bus Tour Transcript

Daré Bioscience, Inc. (DARE) Discusses Women's Health Portfolio and Commercialization Highlights on Virtual Bus Tour August 5, 2026 10:00 AM EDTCompany...

SeekingAlpha·10:20DARE▲+5.3%